Osada Shinji, Imai Hisashi, Sasaki Yoshiyuki, Tanaka Yoshihiro, Okumura Naoki, Nonaka Kenichi, Takahashi Takao, Yamaguchi Kazuya, Yoshida Kazuhiro
Hepatogastroenterology. 2014 May;61(131):722-6.
Surgical indications for resection of synchronous metastasis from colorectal cancer (CRC) are still controversial. 57 patients with synchronous and multiple metastatic liver tumors were studied. 1) The three-year survival rate and MST for synchronous metastasis, 55% and 28.4 ± 15.4 months, were clearly poorer than those of the patients with metachronous, 100% and 39.9 ± 10.8 months. 2) Three-year survival rate and MST for a single tumor were similar to those for multiple tumors but were 83% and 36.6 ± 14.0 months in patients with ≤ 2 tumors, significantly better (p = 0.0127) than those in patients with 3 tumors, 65% and 24.0 ± 13.6 months. 3) In the patients with synchronous liver tumors, 3-year survival rate and MST after staged hepatectomy were significantly better, 82% and 34.5 ± 14.9 months (p = 0.0467), than simultaneous hepatectomy, 29% and 23.9 ± 13.6 months. 4) In patients with repeat hepatectomy, the only difference between first vs. repeat hepatectomy was in tumor number detected, 4.4 ± 1.2 vs. 1.2 ± 0.1. The present data show that neoadjuvant chemotherapy might improve patient prognosis, and with 3 tumors, planning of staged hepatectomy is best, even if technically removed.
结直肠癌(CRC)同步转移灶切除的手术指征仍存在争议。对57例伴有同步性和多发性肝转移瘤的患者进行了研究。1)同步转移患者的三年生存率和中位生存时间(MST)分别为55%和28.4±15.4个月,明显低于异时性转移患者,后者分别为100%和39.9±10.8个月。2)单个肿瘤患者的三年生存率和MST与多个肿瘤患者相似,但肿瘤数量≤2个的患者三年生存率和MST分别为83%和36.6±14.0个月,显著高于肿瘤数量为3个的患者,后者为65%和24.0±13.6个月(p = 0.0127)。3)在同步性肝肿瘤患者中,分期肝切除术后的三年生存率和MST显著更高,分别为82%和34.5±14.9个月(p = 0.0467),而同期肝切除的三年生存率和MST分别为29%和23.9±13.6个月。4)在接受再次肝切除的患者中,首次与再次肝切除之间的唯一差异在于检测到的肿瘤数量,分别为4.4±1.2个和1.2±0.1个。目前的数据表明,新辅助化疗可能改善患者预后,对于有3个肿瘤的患者,即使在技术上能够切除,分期肝切除的规划也是最佳选择。